WALTHAM, Mass., July 8 /PRNewswire-FirstCall/ -- Repligen Corporation
(Nasdaq: RGEN) announced today that it is the first company in North
America to receive certification to BS25999, the new standard for business
continuity management. Business continuity management systems are designed
to build resiliency within an organization and to ensure continued
operations in the event of a business disruption, whether due to a major
disaster or a minor incident. Repligen developed and implemented a business
continuity management system to ensure an uninterrupted supply of its
recombinant Protein A products, a key consumable used by the
biopharmaceutical industry to manufacture drugs called monoclonal
antibodies. Certification of Repligen's business continuity management
system to BS25999 demonstrates that our program meets globally accepted
best practices for business continuity.
"As the world's leading supplier of recombinant Protein A, we felt that
it was important to be on the cutting edge of business continuity to ensure
an uninterrupted supply of products to our customers and ultimately to
patients," stated Walter C. Herlihy, President and Chief Executive Officer
of Repligen Corporation. "We are very proud to be the first company in
North America to have gained certification."
Although Repligen has had a corporate commitment to business continuity
and business continuity planning for several years, certification to
BS25999 has only been available since November 2007. Repligen's
certification was granted by BSI Management Systems, the world's leading
quality management systems registrar.
Repligen is the world's leading supplier of recombinant Protein A, a
consumable used in the manufacture of therapeutic monoclonal antibodies.
There are approximately 20 monoclonal antibodies that have received
regulatory approval with more than 200 products in various stages of
clinical development. The worldwide revenues from this class of drug were
approximately $30 billion in 2007. Monoclonal antibodies are the largest
and fastest growing class of drug in the biopharmaceutical industry.
About Repligen Corporation
Repligen Corporation is a biopharmaceutical company focused on the
development of novel therapeutics for diseases that affect the central
nervous system. In addition, we are the world's leading supplier of
recombinant Protein A, the sales of which partially fund the advancement of
our development pipeline while supporting our financial stability.
Repligen's corporate headquarters are located at 41 Seyon Street, Building
#1, Suite 100, Waltham, MA 02453. Additional information may be requested
from http://www.repligen.com.
This press release contains forward-looking statements which are made
pursuant to the safe harbor provisions of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. The forward-looking statements in this release do not
constitute guarantees of future performance. Investors are cautioned that
statements in this press release which are not strictly historical
statements, including, without limitation, statements regarding current or
future financial performance and position, management's strategy, plans and
objectives for future operations, plans and objectives for product
development, plans and objectives for present and future clinical trials
and results of such trials, plans and objectives for regulatory approval,
litigation, intellectual property, product development, manufacturing plans
and performance such as the anticipated growth in the monoclonal antibody
market and our other target markets and projected growth in product sales,
constitute forward-looking statements. Such forward-looking statements are
subject to a number of risks and uncertainties that could cause actual
results to differ materially from those anticipated, including, without
limitation, risks associated with: the success of current and future
collaborative relationships, the market acceptance of our products, our
ability to compete with larger, better financed pharmaceutical and
biotechnology companies, new approaches to the treatment of our targeted
diseases, our expectation of incurring continued losses, our uncertainty of
product revenues and profits, our ability to generate future revenues, our
ability to raise additional capital to continue our drug development
programs, the success of our clinical trials, our ability to develop and
commercialize products, our ability to obtain required regulatory
approvals, our compliance with all Food and Drug Administration
regulations, our ability to obtain, maintain and protect intellectual
property rights for our products, the risk of litigation regarding our
intellectual property rights, our limited sales and manufacturing
capabilities, our dependence on third-party manufacturers and value added
resellers, our ability to hire and retain skilled personnel, our volatile
stock price, and other risks detailed in Repligen's filings with the
Securities and Exchange Commission. Repligen assumes no obligation to
update any forward-looking information contained in this press release or
with respect to the announcements described herein.
SOURCE Repligen Corporation
 back to top
Related links:
http://www.repligen.com
CONTACT:
Walter C. Herlihy, Ph.D., President and Chief
Executive Officer, +1-781-419-1900, or Laura L. Whitehouse, Vice
President, Market Development, +1-781-419-1812, both of Repligen
Corporation
|
